Velzatinib

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

Gastrointestinal NeoplasmsGastrointestinal Stromal Neoplasm

5 competitors in Gastrointestinal Neoplasms

#DrugCompanyPhaseTrials

1

Velzatinib

GSK

Phase 3

22

GSK5764227

GSK

Preclinical

13

IDRX-42

GSK

Phase 1

24

Drug

EElro Pharma

Preclinical

15

Risvutatug Rezetecan

NNader Sanai

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Gastrointestinal Neoplasms2 trials

Individual Patient Expanded Access for Velzatinib (GSK6042981) in Patients With Gastrointestinal Stromal Tumours With KIT Mutations

Available·GSK··NCT07825701

A Phase 2, Single-arm, Multicenter, Open-Label Study of Velzatinib (GSK6042981) in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib, Sunitinib, Regorafenib, and Pimitespib Therapies (StrateGIST J)

Recruiting·GSK·Phase 2·NCT07689201·24 enrolled

Gastrointestinal Stromal Neoplasm1 trial

A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) Versus Imatinib in Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Recruiting·GSK·Phase 3·NCT07585266·800 enrolled

Details

Drug Info

Related News